Kalaris Therapeutics, Inc.

The company is a clinical-stage biopharmaceutical business focused on developing and commercializing therapeutics for prevalent retinal diseases characterized by substantial unmet medical needs. Its development pipeline centers on treatments for neovascular and exudative eye disorders, specifically neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. Its primary product candidate is TH103, an intravitreally administered anti-vascular endothelial growth factor recombinant fusion protein engineered to enhance intraocular retention and improve durability over existing therapies. Because the company remains in the clinical investigation stage, it currently has no commercialized treatments and primarily directs its clinical efforts toward patients suffering from vision-threatening ocular conditions.

The company retains worldwide rights to develop and commercialize its lead product candidate and plans to establish an internal specialty salesforce upon potential regulatory approval. Its operations center on clinical-stage research and development targeting prevalent conditions that affect millions of patients in the United States, Europe, and worldwide. Specific headquarters location, corporate facility numbers, or administrative office locations are not disclosed in the provided text.

Summary of the business section of Kalaris Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had twenty employees, all of whom were full-time and eleven of whom were engaged in research and development activities.”